Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 4;6(7):e70242.
doi: 10.1002/mco2.70242. eCollection 2025 Jul.

The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells

Michaël Constantinides  1   2 , Loïs Coënon  1 , Paolo Falvo  3 , Caroline Multrier  1 , Davide Lombardi  3 , Francesco Bertolini  3 , Pierre Martineau  4 , Bruno Robert  4 , Guillaume Cartron  2 , Martin Villalba  1   5
Affiliations

The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells

Michaël Constantinides et al. MedComm (2020). .
No abstract available

Keywords: ADCC; B‐cell chronic lymphocytic leukemia; NK cell therapy; engineered mAbs; non‐Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

The patent WO2022023581A1 “Armed NK cells for universal cell therapy” have been filed by M.V., P.M., and B.R. and is licensed to CYTEA BIO. M.V., P.M., and B.R. have been remunerated as advisors by the company CYTEA BIO. The authors declare no other conflicts of interest.

Figures

FIGURE 1
FIGURE 1
eNK arming stability in presence of human IgG and eNK cytotoxicity improvement in vitro and in xenograft model. A) percentage of eNK armed with RTX was, as well as the anti‐RTX MFI ratio normalized to non‐armed eNK 8 h after arming with 10 µg/mL of mAbs for 1 h, washing and incubation with 5 mg/mL of human polyclonal IgG (Privigen). The graphic represents the mean ± SD. B) Survival of target cell line target at E:T (1:1) with eNK (unarmed or armed with WT or SDH‐RTX) or primary tumoral cell at E:T (3:1), (10 B‐CLL with 9 eNK donors and 20 NHL with 16 eNK donors) after 8 h incubation. The graphic represents the mean ± SD of the survival ratio of RAJI or DAUDI cells (compared to MOLM‐13 cells) or tumor cell survival, normalized to 100%. C) Dot plot represents hCD19 and hCD20 expression by PDX cell line, selected as: 7AAD‐ and hCD45+ single cells. D) Depicts xenograft results for 25 male mice engrafted with the PDX line. Red arrows represent days (d10‐14‐17) of eNK injections (8 × 106 cells). Graphics D represents mean ± SEM of average radiance reflection xenograft tumoral mass in the animals’ femurs. Tukey's test compared to control was used. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
See this image and copyright information in PMC

References

    1. Moore G. L., Chen H., Karki S., and Lazar G. A., “Engineered Fc Variant Antibodies With Enhanced Ability to Recruit Complement and Mediate Effector Functions,” MAbs 2, no. 2 (2010): 181–189. - PMC - PubMed
    1. Dosani T., Carlsten M., Maric I., and Landgren O., “The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of MM and Their Uses in Immunotherapies,” Blood Cancer Journal 5, no. 4 (2015): e306–e306. - PMC - PubMed
    1. Kilgour M. K., Bastin D. J., Lee S. H., Ardolino M., McComb S., and Visram A., “Advancements in CAR‐NK Therapy: Lessons to be Learned From CAR‐T Therapy,” Frontiers in Immunology 14 (2023): 1166038. - PMC - PubMed
    1. Marin D., Li Y., Basar R., et al. “Safety, Efficacy and Determinants of Response of Allogeneic CD19‐Specific CAR‐NK Cells in CD19+ B Cell Tumors: A Phase 1/2 Trial,” Nature Medicine 30 (2024): 772–784. - PMC - PubMed
    1. Coënon L., Geindreau M., Ghiringhelli F., Villalba M., and Bruchard M., “Natural Killer Cells at the Frontline in the Fight Against Cancer,” Cell Death & Disease 15, no. 8 (2024): 614. - PMC - PubMed

LinkOut - more resources